Six‐month outcomes in postapproval HeartMate3 patients: A single‐center US experience

BACKGROUND: The European CE Mark approval study and the MOMENTUM 3 trial demonstrated safety and a reduction in hemocompatibility‐related adverse events with the use of HeartMate 3 (HM3) device. This single‐center study investigated the real‐world experience in HM3 patients since FDA approval. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansal, Aditya, Akhtar, Faisal, Desai, Sapna, Velasco‐Gonzalez, Cruz, Bansal, Anirudh, Teagle, Angie, Shridhar, Avni, Webre, Karen, Ostrow, Sheila, Fary, David, Parrino, Patrick Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320844/
https://www.ncbi.nlm.nih.gov/pubmed/35385586
http://dx.doi.org/10.1111/jocs.16452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320844/
https://www.ncbi.nlm.nih.gov/pubmed/35385586
http://dx.doi.org/10.1111/jocs.16452

Ejemplares similares